|
Needs Statement
The incidence of diabetes and
cardiometabolic disorders is increasing
rapidly, bringing with it a need
for new effective treatments. Obesity
also continues to rise, leading to higher
incidences of hypertension, dislipidemia,
heart disease, and diabetes. 1,2
Approximately 65% of individuals
with diabetes die of heart disease or
stroke, and the risk for these conditions
two to four times higher in individuals
with diabetes than in individuals
without diabetes. 3
New research is exploring novel
mechanisms to treat obesity, in an effort
to reduce its adjunctive effects. One
particular method, targeting the endocannabinoid
system (ECS), appears
promising. 4 The ECS is involved in
body fat regulation, but the system can
become unbalanced and overactive with
excessive food intake. 5,6 This monograph
discusses the possible potential
uses for ECS anatagonists in treating
obesity and associated cardiovascular
disorders.
| 
